Atom Bioscience planning phase III gout trial after encouraging mid-stage readout - BioWorld Online

Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd., a company developing an oral a urate anion exchanger 1 inhibitor for the potential treatment of chronic gout, said results of a phase IIa trial show that its lead candidate, ABP-671, reduced serum uric acid levels to less than 6 mg/dL, below the clinically defined threshold of 7 mg/dL for hyperuricemia, or excess of uric acid in the blood, which leads to gout.

BioWorld Clinical Inflammatory China

Adblock test (Why?)

Comments

Post a Comment

Popular posts from this blog

“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more

Image
“Opioids in America, Part 3: The other side of the crisis - Greeley Tribune” plus 1 more Opioids in America, Part 3: The other side of the crisis - Greeley Tribune Posted: 31 Oct 2020 04:20 PM PDT Editor's Note: This is Part 3 of a three-part series looking into the opioid epidemic across the U.S., rehabilitation options in Weld County and stories from people who have overcome or are currently fighting addiction to opioids. Like many things, there's another side to the opioid crisis. While the addiction to opioids is a problem that needs to be addressed, people who are using the drugs exclusively as prescribed — and who still truly need it from a medical perspective — have been swept up in what some have seen as government's knee-jerk reaction to the crisis. In having their ability limited to get the drugs they need in order to function, many of these patients are left suffering debilitating pain. Richard Mark VanWormer w
Read more

“Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet” plus 4 more

Image
“Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet” plus 4 more Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet Evaluation of the novel coronavirus disease in Turkish children: Preliminary outcomes - Wiley Coronavirus recovery: Most common post-COVID signs which could indicate signs of long term trouble - Times of India What you – and doctors – should watch for if you have COVID-19 - The Conversation US Coronavirus in San Diego and California: Latest updates and news - CBS News 8 Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study - The Lancet Posted: 08
Read more

“Ground glass opacity: Causes, symptoms, and treatments - Medical News Today” plus 1 more

Image
“Ground glass opacity: Causes, symptoms, and treatments - Medical News Today” plus 1 more Ground glass opacity: Causes, symptoms, and treatments - Medical News Today Posted: 30 Mar 2021 03:14 AM PDT Ground glass opacity (GGO) refers to the hazy gray areas that can show up in CT scans or X-rays of the lungs. These gray areas indicate increased density inside the lungs. The term comes from a technique in glassmaking during which the surface of the glass is blasted by sand. This technique gives the glass a hazy white or frosted appearance. There are many potential causes of GGO, including infections, inflammation , and growths. One 2020 review also found that GGO was the most common anomaly among people with COVID-19-related pneumonia. This article will look at what GGO is, some of its causes, and its treatment options. GGO refers to gray areas that can show up in lung X-rays or CT scans . Normally, the lungs appear black
Read more